Vol. 5 No. 7 (2025)
Reimbursement Reviews

Fidaxomicin

decorative image of the issue cover

Published July 30, 2025

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses fidaxomicin (Dificid), 200 mg tablet for oral administration.
  • Indication under consideration for reimbursement: Treatment of difficile infection for adult patients who have initial episode or first recurrence.